about
Simultaneous fMRI-PET of the opioidergic pain system in human brainNicotine blocks brain estrogen synthase (aromatase): in vivo positron emission tomography studies in female baboonsA philosophy for CNS radiotracer designVisualizing epigenetics: current advances and advantages in HDAC PET imaging techniques(11)C[double bond, length as m-dash]O bonds made easily for positron emission tomography radiopharmaceuticalsA selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related testsPET neuroimaging studies of [(18)F]CABS13 in a double transgenic mouse model of Alzheimer's disease and nonhuman primatesNasal neuron PET imaging quantifies neuron generation and degenerationNeuroinflammatory component of gray matter pathology in multiple sclerosisEvaluation of potential PET imaging probes for the orexin 2 receptors.In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs.In vivo imaging of adult human hippocampal neurogenesis: progress, pitfalls and promisePET Neurochemical Imaging Modes.In Vivo Imaging of Human Neuroinflammation.Application of palladium-mediated (18)F-fluorination to PET radiotracer development: overcoming hurdles to translation.High relaxivity gadolinium hydroxypyridonate-viral capsid conjugates: nanosized MRI contrast agents.Modification of aniline containing proteins using an oxidative coupling strategy.Magnetic resonance contrast agents from viral capsid shells: a comparison of exterior and interior cargo strategies.Synthesis of [(11)C]Bexarotene by Cu-Mediated [(11)C]Carbon Dioxide Fixation and Preliminary PET Imaging.Radionuclide labeling and evaluation of candidate radioligands for PET imaging of histone deacetylase in the brainModular strategies for PET imaging agentsExpression of HDAC2 but Not HDAC1 Transcript Is Reduced in Dorsolateral Prefrontal Cortex of Patients with Schizophrenia.Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboonsSynthesis and imaging validation of [¹⁸F]MDL100907 enabled by Ni-mediated fluorination.Image-guided synthesis reveals potent blood-brain barrier permeable histone deacetylase inhibitors.Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography.Evaluation of [(11)C]metergoline as a PET radiotracer for 5HTR in nonhuman primates.A fluoride-derived electrophilic late-stage fluorination reagent for PET imaging.PET imaging demonstrates histone deacetylase target engagement and clarifies brain penetrance of known and novel small molecule inhibitors in rat.Class I HDAC imaging using [ (3)H]CI-994 autoradiographyFDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors.Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET.Late stage benzylic C-H fluorination with [¹⁸F]fluoride for PET imaging.Dynamic functional imaging of brain glucose utilization using fPET-FDG.Virtually instantaneous, room-temperature [(11)C]-cyanation using biaryl phosphine Pd(0) complexesEvidence for brain glial activation in chronic pain patients.Targeted fluorination with the fluoride ion by manganese-catalyzed decarboxylation.Kinetic Analysis and Quantification of [¹¹C]Martinostat for in Vivo HDAC Imaging of the Brain.PET imaging of fatty acid amide hydrolase with [(18)F]DOPP in nonhuman primates.Development of a Fluorinated Class-I HDAC Radiotracer Reveals Key Chemical Determinants of Brain Penetrance.
P50
Q24580478-2CED5D93-D671-4D13-8861-C82AB4936069Q24608685-F152F8EB-0ADD-43B0-804E-46B3C3160B38Q26853140-0BECAD38-3F5B-4569-81A4-A494E451CDB4Q26862755-A03AAFD3-37E1-4B7B-A186-2BC013AAA29DQ28066107-C46707DD-2959-4A6A-9BCE-6E575E9EF040Q28535325-4C062041-27E0-4860-8992-91381EB3DB83Q28833503-9FFA16F6-C051-48FB-9D34-0C418439EB4AQ29048644-5A982A7F-9564-4651-85B6-B83A763D9B8CQ29398383-44D27386-41C5-4C88-9331-A21C154019D8Q30555478-D3841218-E570-48F6-BD4B-76A4EA59487DQ30591009-A6C42274-1CF8-4F1F-9309-B75BB228E4D1Q30594072-008327C3-47F7-480B-AA81-F3291E59E942Q31033080-54D76C6C-90F8-4500-8283-3068623D1D47Q31059488-26B9267E-E795-439C-9F7C-05C078388583Q31114482-6C4695D3-AFE9-42BF-A365-88FAD41147F3Q31145370-AA6A371A-6F8C-4D37-AC00-5CAC4817F597Q33265470-0B319DD5-36F1-4CA2-A937-C2A3C1FE1871Q33290823-03DDF818-152E-4A52-A1F4-8988C280907CQ33461960-12514E31-1D1A-4ACC-BABD-E527B8DF9E80Q33556502-2D8FBD7C-66B6-4C8A-9067-87681D1D2B7EQ33643481-67F46DC0-8005-4FF5-A456-99F91528861DQ33703849-49AC299B-A109-457B-968F-3F00F4850971Q33835981-34717482-AB91-46E7-A7DE-5786EBAA40DCQ33918178-B08D84F4-9518-43F7-804B-18B31ACA2A0FQ33918201-6AE3ED2D-78FB-4018-B18F-637E4706E574Q34013315-4BC05F98-D9D9-4FF6-8371-82E036580279Q34183122-F275BD20-766C-4057-8857-1D2DF93E77D4Q34230071-4269425B-435D-4281-8AB5-CE7D77C27EACQ34343350-152B3147-C419-4E0B-A71E-FB2D1F5BD7C6Q34353711-4DF3F355-57F6-4124-B05C-4540234904D8Q34354229-7380C0F0-5A67-4342-9CBF-838533B3BE2AQ34361155-0A37C282-CEA5-46B5-A792-82709F145548Q34417088-DA7601D1-AE0C-4A1D-B157-40CA12C9535CQ34425194-B606D5FA-8FE6-44DC-8F18-9407E6C638E1Q34456910-1C6829FD-961B-4687-A1AC-F37309D4F8EEQ34457857-EDC8D851-1FB4-46A1-9FE9-40CD6D1E9124Q34465519-9A213A00-8A1B-41C2-8EFD-59DEC99F1A27Q34467002-7419D2B0-0A3F-481B-8B9A-52EE356AC1BDQ34473739-9F86C5F7-9597-4C66-B3C5-2FBD5D5FA6CDQ34505403-D5A13D82-64E5-4C13-8D5F-CC9ED88673D0
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jacob M. Hooker
@ast
Jacob M. Hooker
@en
Jacob M. Hooker
@es
Jacob M. Hooker
@nl
Jacob M. Hooker
@sl
type
label
Jacob M. Hooker
@ast
Jacob M. Hooker
@en
Jacob M. Hooker
@es
Jacob M. Hooker
@nl
Jacob M. Hooker
@sl
prefLabel
Jacob M. Hooker
@ast
Jacob M. Hooker
@en
Jacob M. Hooker
@es
Jacob M. Hooker
@nl
Jacob M. Hooker
@sl
P106
P1153
16417545700
P31
P3835
jacob-hooker
P496
0000-0002-9394-7708